Floatz logo

Rotigotine

Anxiety Disorders

Johns Hopkins UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Anxiety Disorders cohort.

Asset / SponsorPhaseRating
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 4BBB
Risperdal
Tianjin Medical University General Hospital
Phase 4BBB
Olanzapine
Tianjin Medical University General Hospital
Phase 4BBB
FLUOXETINE
Hannover Medical School
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Theresa Jacob, PhD, MPH
Phase 4BBB

View all 50 →

Same molecule, other indications

Rotigotine is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
Nocturnal HypokinesiaDormant
BB
Indicative ·
65 / 100
View asset →
ApathyDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →